Another Priority Review Voucher (PRV) Sold, This Time for $125 Million
Here’s an important follow-up from Zach Brennan at the RAPS website on the FDA’s priority review voucher (PRV) program. Sarepta just sold its PRV (which it...
Read More
-
About Pathophilia
Zach Brennen at Regulatory Focus: The FDA’s PRV Program Is at a Legislative Juncture
This is a MUST READ from Zachary Brennen at RAPS/Regulatory Focus on the review and potential reauthorization of the controversial priority review voucher (PRV) program...
Read More
Citron Research Drops White-Paper Bomb on Questcor
Citron Research, a stock-commentary website, has dropped a (another) bomb on Questcor Pharmaceuticals (QCOR). According to Citron’s latest research, QCOR’s...
Read More
“Elixir” Available Now
Announcing the availability of my new book, Elixir: The American Tragedy of a Deadly Drug, at Amazon. Elixir is the first detailed account of the scores of American...
Read More
Coming Soon: Elixir–The American Tragedy of a Deadly Drug
After more than 10 years of research, I am happy (relieved) to announce my soon-to-be published nonfiction book Elixir: The American Tragedy of a Deadly Drug. Look for...
Read More
Healthcare.gov Up and Running–?
It’s slow, but healthcare.gov now appears to be operational. This morning, I was able to log in, enroll, and compare plans. Although YMMV, perhaps depending on...
Read More